Irinotecan Fresenius Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Fresenius Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous administration. It is employed in the treatment of metastatic colorectal cancer and other solid tumours, typically as part of multi‑drug chemotherapy protocols designed for adult patients.

GNH USA supplies Irinotecan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and offers global logistics support.

Irinotecan is a topoisomerase I inhibitor used in chemotherapy regimens for colorectal and other solid tumours.

Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine and oxaliplatin. Advanced colorectal cancer: used after failure of first‑line therapy to achieve disease control. Other solid tumours: incorporated into combination protocols for gastric, pancreatic and lung cancers. Locally advanced colorectal cancer: employed to downstage tumours before surgical resection.

Irinotecan may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhoea: can be severe and require supportive care. - Nausea and vomiting: often managed with anti‑emetics. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe diarrhoea (colitis): may lead to dehydration and electrolyte imbalance. - Allergic reactions: rash, bronchospasm or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Tumour lysis syndrome: metabolic disturbances from rapid tumour cell breakdown. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating Irinotecan therapy, clinicians should assess several safety parameters.

Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust dosing in hepatic impairment. Hydration: maintain adequate fluids to reduce risk of severe diarrhoea. Avoid concurrent strong CYP3A4 inhibitors: may increase drug exposure. Pregnancy: use only if potential benefits justify potential fetal risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan interacts with several medicines that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase toxicity. - UGT1A1 inhibitors (e.g., atazanavir): raise active metabolite levels. - Concurrent myelosuppressive agents: heightened bone‑marrow suppression. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - Fluoropyrimidines (e.g., 5‑FU): monitor for additive gastrointestinal toxicity. - Platinum compounds (e.g., oxaliplatin): watch for cumulative myelosuppression.